Extended Data Fig. 3: Clinical trajectory, inflammatory markers, and CAR-T expansion in patient I001 following ESO-T01 infusion. | Nature Medicine

Extended Data Fig. 3: Clinical trajectory, inflammatory markers, and CAR-T expansion in patient I001 following ESO-T01 infusion.

From: In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study

Extended Data Fig. 3: Clinical trajectory, inflammatory markers, and CAR-T expansion in patient I001 following ESO-T01 infusion.

a, Temporal changes in body temperature and blood pressure with concurrent clinical interventions. The patient developed grade 3 CRS within 2 hours of infusion, presenting with fever, hypotension, hypoxemia, and tachycardia. Management consisted of high-dose corticosteroids, tocilizumab, renal replacement therapy, dopamine, and high-flow oxygen delivered in a hematology ward equipped for ICU-level monitoring. Oxygen flow rates (L/min) are annotated along the horizontal bar. b, Serum cytokines (IL-6, IL-8, IL-10) and ferritin showed a hyperacute surge coinciding with CRS onset, followed by a decline after supportive therapy. c, Circulating CAR transgene copies became detectable after Day 4, while serum IgG-κ M protein showed a transient decline, interpreted as an immune-related fluctuation rather than tumor lysis.Abbreviations: CAR, chimeric antigen receptor; CRS, cytokine release syndrome; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; LOD, limit of detection.

Back to article page